NASDAQ:TSHA Taysha Gene Therapies Q3 2026 Earnings Date & Estimates $4.33 +0.24 (+5.87%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$4.29 -0.04 (-0.92%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Taysha Gene Therapies is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Taysha Gene Therapies in Q3 2026Taysha Gene Therapies is expected to post earnings of -$0.1286 per share on revenue of $756 thousand. In the same quarter a year earlier Taysha Gene Therapies reported -$0.09 per share. Taysha Gene Therapies last reported on August 11, 2026, posting -$0.13 per share and missing the -$0.1133 consensus estimate. Taysha Gene Therapies has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1286Expected Revenue$756 thousandPrior-Year EPS-$0.09Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.13 (Missed by -$0.0167)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Taysha Gene Therapies Q3 2026 Earnings FAQ When does Taysha Gene Therapies report Q3 2026 earnings? Taysha Gene Therapies (NASDAQ:TSHA) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Taysha Gene Therapies' Q3 2026 earnings call? Taysha Gene Therapies' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Taysha Gene Therapies? Analysts expect Taysha Gene Therapies to post earnings of -$0.1286 per share for Q3 2026. How much revenue is Taysha Gene Therapies expected to report? The consensus revenue estimate for Taysha Gene Therapies is $756 thousand for Q3 2026. Taysha Gene Therapies Earnings HeadlinesTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 6 at 8:00 AM | globenewswire.comTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12November 5 at 8:00 AM | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)Taysha Gene Therapies (TSHA) Set to Post Quarterly Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comTaysha Gene Therapies (TSHA) Stock Looks Rich Against Book ValueOctober 30, 2026 | uk.finance.yahoo.comDoes Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?October 19, 2026 | finance.yahoo.comSee More Taysha Gene Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Taysha Gene Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your email. Email Address About Taysha Gene TherapiesTaysha Gene Therapies (NASDAQ:TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options. Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy. These investigational therapies are designed to deliver functional genetic material to affected cells and are being evaluated through clinical and preclinical research. None of the company’s product candidates has been approved for commercial use. Founded in 2019 and headquartered in Dallas, Texas, Taysha conducts research and clinical development activities primarily in the United States while seeking to advance therapies for patients with rare neurological diseases worldwide. Its programs are supported by proprietary gene therapy technologies intended to improve the delivery and expression of therapeutic genes in the nervous system.View Taysha Gene Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Sandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
